BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1339 related articles for article (PubMed ID: 29758333)

  • 1. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B.
    van Bömmel F; Berg T
    Hepatol Commun; 2021 Oct; 5(10):1632-1648. PubMed ID: 34558833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
    J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
    Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
    Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
    Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
    Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss.
    Zimmer CL; Rinker F; Höner Zu Siederdissen C; Manns MP; Wedemeyer H; Cornberg M; Björkström NK
    J Infect Dis; 2018 Apr; 217(10):1656-1666. PubMed ID: 29471497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
    J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
    He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
    BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy.
    Li Y; Wen C; Gu S; Wang W; Guo L; Li CK; Yi X; Zhou Y; Dong Z; Fu X; Zhong S; Wang Y; Huang K; Yin J; Zhong C; Liang X; Fan R; Chen H; Jiang D; Zhang X; Sun J; Tang L; Peng J; Hou J
    Hepatology; 2023 Aug; 78(2):592-606. PubMed ID: 36896974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B.
    Kranidioti H; Manolakopoulos S; Kontos G; Breen MS; Kourikou A; Deutsch M; Quesada-Del-Bosque ME; Martinez-Nunez RT; Naiyer MM; Woelk CH; Sanchez-Elsner T; Hadziyannis E; Papatheodoridis G; Khakoo SI
    J Viral Hepat; 2019 Jun; 26(6):697-709. PubMed ID: 30702196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.